Clinical Trial: NCT04736173
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Arcus Biosciences, Inc. |
| Information Provided By: | Arcus Biosciences, Inc. |
| Last Update Posted: | 2026-10-19 |
Study Overview
Brief Summary
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Official Title
Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Intervention / Treatment
- Drug: Domvanalimab
- Drug: Zimberelimab
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: Pemetrexed
- Drug: Pembrolizumab
Other Study ID Numbers
- ARC-10
- 2020-003562-39
- PHRR210222-003371
- 2022-503071-28-00
Start Date (Actual)
2021-02-08
Primary Completion Date (Actual)
2026-09-17
Study Completion Date (Actual)
2026-09-17
Enrollment (Actual)
169
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Arcus Biosciences, Inc. |
| Information Provided By: | Arcus Biosciences, Inc. |
| Last Update Posted: | 2026-10-19 |
Study Overview
Brief Summary
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Official Title
Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Intervention / Treatment
- Drug: Domvanalimab
- Drug: Zimberelimab
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: Pemetrexed
- Drug: Pembrolizumab
Other Study ID Numbers
- ARC-10
- 2020-003562-39
- PHRR210222-003371
- 2022-503071-28-00
Start Date (Actual)
2021-02-08
Primary Completion Date (Actual)
2026-09-17
Study Completion Date (Actual)
2026-09-17
Enrollment (Actual)
169
Study Type
Interventional
Phase
Phase 2